Cargando…

Realities in cost-effectiveness analyses: a study of castration-resistant prostate cancer patients using a medical claims database

Previous cost-effectiveness analyses (CEAs) of abiraterone for castration-resistant prostate cancer (CRPC) patients have not shown favorable results for this new drug. These CEAs were generally conducted based on models used in clinical trials, where comparisons were made with patients given placebo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kunisawa, Susumu, Tange, Chihiro, Shimozuma, Kojiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628043/ https://www.ncbi.nlm.nih.gov/pubmed/26543759 http://dx.doi.org/10.1186/s40064-015-1413-9

Ejemplares similares

Direct health care cost of treatment and medication of biliary atresia patients using the National Database of Health Insurance Claims and Specific Health Checkups
por: Hoshino, Eri, et al.
Publicado: (2022)

Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization: Analysis of a medical claims database
por: Mohamad Al-Ali, Badereddin, et al.
Publicado: (2016)

Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review
por: Grochtdreis, Thomas, et al.
Publicado: (2018)

Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
por: Kreis, Kristine, et al.
Publicado: (2020)

Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims
por: Freedland, Stephen J., et al.
Publicado: (2023)

Trajectories of end-of-life medical and long-term care expenditures for older adults in Japan: retrospective longitudinal study using a large-scale linked database of medical and long-term care claims
por: Teraoka, Emi, et al.
Publicado: (2021)

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
por: Urso, Luca, et al.
Publicado: (2023)

Second-line Hormonal Therapy for the Management of Metastatic Castration-resistant Prostate Cancer: a Real-World Data Study Using a Claims Database
por: Liu, Jui-Ming, et al.
Publicado: (2020)

Regional medical inter-institutional cooperation in medical provider network constructed using patient claims data from Japan
por: Ohki, Yu, et al.
Publicado: (2022)

Temporal trends of medical cost and cost-effectiveness in sepsis patients: a Japanese nationwide medical claims database
por: Oami, Takehiko, et al.
Publicado: (2022)

Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
por: Dragomir, Alice, et al.
Publicado: (2014)

Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
por: Pollard, Matthew E., et al.
Publicado: (2017)

Cost Analysis in Helicobacter pylori Eradication Therapy Based on a Database of Health Insurance Claims in Japan
por: Tokunaga, Kengo, et al.
Publicado: (2021)

Challenges in generating costs and utilisation rates associated with castration-resistant prostate cancer
por: Bourke, Siobhan, et al.
Publicado: (2014)

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis
por: Charbonnel, Bernard, et al.
Publicado: (2017)

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
por: Lorente, David, et al.
Publicado: (2016)

Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials
por: Grayling, Michael J., et al.
Publicado: (2022)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
por: Su, Dan, et al.
Publicado: (2021)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis
por: Schultz, Neil M., et al.
Publicado: (2018)

The Impact of Patient Profiles and Procedures on Hospitalization Costs through Length of Stay in Community-Acquired Pneumonia Patients Based on a Japanese Administrative Database
por: Uematsu, Hironori, et al.
Publicado: (2015)

Postoperative mortality analysis on nationwide data from diagnosis procedure combination database in Japan
por: Kunisawa, Susumu
Publicado: (2023)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database
por: Ogino, Mieko, et al.
Publicado: (2016)

Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union
por: Clark, Marci J, et al.
Publicado: (2014)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
por: de Leeuw, Renée, et al.
Publicado: (2020)

Effects of preoperative oral management by dentists on postoperative outcomes following esophagectomy: Multilevel propensity score matching and weighting analyses using the Japanese inpatient database
por: Shin, Jung-ho, et al.
Publicado: (2019)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Chemotherapy options in castration-resistant prostate cancer
por: Teply, Benjamin A., et al.
Publicado: (2016)

Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis
por: Zhong, Lixian, et al.
Publicado: (2013)

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study
por: Restelli, Umberto, et al.
Publicado: (2017)

Prevalence, treatments and medical cost of multiple sclerosis in Japan based on analysis of a health insurance claims database
por: Ogino, Mieko, et al.
Publicado: (2017)

Comorbidities and costs in HIV patients: A retrospective claims database analysis in Germany
por: Christensen, Stefan, et al.
Publicado: (2019)

Factors associated with high‐dose antipsychotic prescriptions in outpatients with schizophrenia: An analysis of claims data from a Japanese prefecture
por: Takahashi, Tatsuichiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g4kcccs2t8u1e1jprqgf51u73c